SCHEMBL4883267

SCHEMBL4883267

CCOC(=O)c1c(NC(=O)c2ccc(Cl)cc2)nc(CC)n1Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.47
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
ADORA3 P0DMS8 1/20 0.46
GAA P10253 1/20 0.46
CYP1A2 P05177 2/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
GABRA2 P47869 1/20 0.43
GABRB2 P47870 1/20 0.43
DRD2 P14416 3/20 0.43
TBXA2R P21731 3/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4890027 0.89 ADORA3 (0.43) HTTSMN1; SMN2RAB9ANPC1ADORA3
SCHEMBL4576362 0.87 CYP19A1 (0.45) CYP19A1HTTSMN1; SMN2RAB9ANPC1
SCHEMBL4893882 0.85 CNR2 (0.42) HTTSMN1; SMN2RAB9ANPC1ADORA3
SCHEMBL13325305 0.80 HTT (0.49) HTTSMN1; SMN2RAB9ANPC1ADORA3
SCHEMBL7878433 0.80 CYP19A1 (0.54) CYP19A1SMN1; SMN2GAACYP1A2CYP2C9
SCHEMBL13325250 0.78 PDE6D (0.49) HTTSMN1; SMN2RAB9ANPC1ADORA3
SCHEMBL4576601 0.78 ADORA3 (0.49) CYP19A1HTTSMN1; SMN2RAB9ANPC1
SCHEMBL4895350 0.78 ALDH1A1 (0.54) CYP19A1SMN1; SMN2RAB9ANPC1GAA
SCHEMBL13325204 0.77 ALDH1A1 (0.55) NPC1ADORA3GAACYP1A2CYP2C9
SCHEMBL4576818 0.77 SMN1; SMN2 (0.44) HTTSMN1; SMN2RAB9ANPC1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators ASTRAZENECA AB (SE) 2008-12-18 US claimed
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators ASTRAZENECA AB (SE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators GABRB1, GABBR2, GABRB2 CYP19A1 3847/4885HTT 4375/4885SMN1; SMN2 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.